ARIAD Pharmaceuticals (NASDAQ:ARIA) has shown a rise of 6.7% or 2,142,030 shares in the short positions. The bets have increased to 34,123,404 shares on June 15,2016 from 31,981,374 shares on May 31,2016. With respect to the floated shares, the shorts are 18.5%. The days to cover are calculated to be 7, using the standard per day volume of 4,726,761 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
ARIAD Pharmaceuticals (NASDAQ:ARIA): The stock opened at $7.13 on Friday but the bulls could not build on the opening and the stock topped out at $7.46 for the day. The stock traded down to $7.08 during the day, due to lack of any buying support eventually closed down at $7.18 with a loss of -4.77% for the day. The stock had closed at $7.54 on the previous day. The total traded volume was 7,073,607 shares.
The company shares have dropped -9.11% from its 1 Year high price. On Aug 28, 2015, the shares registered one year high at $10.07 and the one year low was seen on Feb 11, 2016. The 50-Day Moving Average price is $7.97 and the 200 Day Moving Average price is recorded at $6.52.
ARIAD Pharmaceuticals (NASDAQ:ARIA) has tumbled 4.52% during the past week and has dropped 12.55% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 2.94%. ARIAD Pharmaceuticals (NASDAQ:ARIA) has underperformed the index by 9.9% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
ARIAD Pharmaceuticals, Inc. is a global oncology company. The Company is engaged in the discovery, development and commercialization of small molecule drug indicated for the treatment of cancer. The Companys product pipeline includes Iclusig (ponatinib), brigatinib (AP26113), AP32788 and ridaforolimus. Iclusig is a tyrosine kinase inhibitor (TKI), which is approved in the United States, Europe and Australia for the treatment of adult patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Brigatinib is an investigational inhibitor of anaplastic lymphoma kinase (ALK). AP32788, is an orally active TKI. Ridaforolimus is an investigational inhibitor of the mammalian target of rapamycin (mTOR).